EverGlade Consulting Helps GeoVax Secure up to $45 Million in BARDA Funding
EverGlade Consulting Helps GeoVax Secure up to $45 Million in BARDA Funding
By Stephen Richardson, Managing Consultant and Eric Jia-Sobota, Founder
由Managing Consultant Stephen Richardson和Founder Eric Jia-Sobota撰写
HOUSTON, Aug. 28, 2024 /PRNewswire/ -- EverGlade Consulting, a national consulting firm, has helped GeoVax Labs, Inc successfully secure up to $45 million in funding to advance the development of GEO-CM04S1, GeoVax's dual-antigen next-generation COVID-19 vaccine through the Rapid Response Portfolio Vehicle (RRPV) consortium funded by the Biomedical Advanced Research and Development Authority ("BARDA").
休斯顿，2024年8月28日 / PRNewswire / - 全国咨询公司EverGlade Consulting已帮助geovax labs成功获得4500万美元的资金，以推进GEO-CM04S1的研发，这是GeoVax的双抗原下一代COVID-19疫苗，通过生物医药先进研究和发展局（"BARDA"）资助的快速响应组合车（RRPV）财团。
The $45 million in BARDA funding will fund the manufacturing of clinical materials and support for the Phase 2b clinical trial. Under the agreement, GeoVax will sponsor a 10,000-participant, randomized, Phase 2b double-blinded study to compare the efficacy, safety, and immunogenicity of GEO-CM04S1 with a FDA-approved mRNA COVID-19 vaccine. Preparations for the study are underway, and execution of the study will be fully funded by BARDA under its Clinical Studies Network.
4500万美元的BARDA资金将用于资助临床材料的生产和支持第20亿临床试验。根据协议，geovax labs将资助一项由1万名参与者组成的、随机分组的、第20亿期双盲研究，以比较GEO-CM04S1的疗效、安全性和免疫原性与一种获得FDA批准的mRNA COVID-19疫苗。该研究的准备工作正在进行中，并且该研究的执行将完全由BARDA在其临床研究网络下资助。
"At EverGlade we pride ourselves on empowering our clients through strategic guidance and robust support. The recent BARDA award to GeoVax is not just a win for our client, but a promising advancement for global health. We are honored to contribute to the development of innovative vaccine technologies that aim to protect communities and save lives," stated EverGlade Consulting Founder, Eric Jia-Sobota
"在EverGlade，我们以战略指导和强有力的支持赋予客户力量为傲。最近BARDA授予geovax labs的奖项不仅是我们客户的胜利，也是全球卫生的一个有希望的进步。我们很荣幸能够为旨在保护社区和拯救生命的创新疫苗技术的发展做出贡献。" EverGlade Consulting创始人Eric Jia-Sobota表示。
Funding for this award is provided under Project NextGen, a $5 billion initiative by HHS to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19 than the first generation COVID vaccines and medicines. BARDA is supporting the development of new vaccines and therapeutics to better address the waning immunity and resistance to current and future SARS-CoV2 viral strains. GeoVax's vaccine candidate provides many of the features identified by BARDA including broader protection among variants of concern (VOC) and a longer duration of protection.
该奖项的资金来自HHS下一代项目，该项目是一个50亿美元的倡议，旨在推进一系列新的创新疫苗和治疗手段，提供比第一代COVID疫苗和药物更广泛和更持久的保护。BARDA支持开发新的疫苗和治疗手段，以更好地应对当前和未来SARS-CoV2病毒株的减退免疫和对抗力。geovax labs的疫苗候选者提供了BARDA识别的许多特征，包括对关注的变种（VOC）更广泛的保护和更长时间的保护。
"Geovax is a proud and highly satisfied client of EverGlade. We recommend this team to those in pursuit of and as a recipient of a BARDA award," stated GeoVax Labs Chairman & CEO, David Dodd.
"geovax labs是EverGlade引以为豪和高度满意的客户。我们向那些正在追求并获得BARDA奖项的人推荐这个团队。" geovax labs主席兼首席执行官David Dodd表示。
If your company has considered applying for BARDA funding, your federal funding journey starts here. EverGlade Consulting is a national consulting firm that helps organizations win and manage federal awards. We offer services ranging from Pursuit, Proposal and Post-Award support to comply with federal regulations at agencies including BARDA, ASPR, NIH, DTRA, JPEO, DOD, DIU, DOE, and DARPA.
如果贵公司考虑申请BARDA基金，您的联邦资金之旅从这里开始。EverGlade Consulting是一家全国性咨询公司，帮助组织赢得和管理联邦奖励。我们提供的服务包括追求、提案和后奖励支持，以便在包括BARDA、ASPR、NIH、DTRA、JPEO、DOD、DIU、DOE和DARPA在内的机构遵守联邦规章。
For additional information about EverGlade Consulting, reach out to:
如需了解更多关于EverGlade Consulting的信息，请联系：
[email protected]
[email protected]
SOURCE EverGlade Consulting
来源：EverGlade Consulting